Sanofi (SNY) Payables (2009 - 2026)
Sanofi (SNY) posted Payables of $8.3 billion for Q2 2026, down 3.01% sequentially from $8.6 billion in Q4 2025, and up 3.77% YoY from $8.0 billion in Q2 2025.
Sanofi (SNY) Payables (2009 - 2026) Analysis & Trends
Sanofi has reported Payables for 18 years, with the latest figure at $8.3 billion in Q2 2026.
- Quarterly Payables rose 3.77% year-over-year to $8.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.3 billion (up 3.77% YoY) and the FY2025 annual result came in at $8.6 billion, up 6.19% from the prior year.
- Payables declined to $8.3 billion in Q2 2026 per SNY's latest filing, from $8.6 billion in the prior quarter.
- Over five years, Payables peaked at $8.6 billion in Q4 2025 and troughed at $7.0 billion in Q4 2022.
- A 5-year average of $7.9 billion and a median of $8.0 billion in 2025 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables declined 1.68% in 2022, then climbed 14.61% in 2023.
- Over 5 years, Payables stood at $7.0 billion in 2022, then climbed by 13.43% to $7.9 billion in 2023, then advanced by 2.34% to $8.1 billion in 2024, then increased by 6.19% to $8.6 billion in 2025, then slipped by 3.01% to $8.3 billion in 2026.
- According to Business Quant data, Payables over the past three periods registered $8.3 billion, $8.6 billion, and $8.0 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 470.14 Bn | 463.57 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 379.19 Bn | 372.05 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 302.86 Bn | 295.17 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 236.75 Bn | 222.76 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 182.65 Bn | 179.47 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 161.71 Bn | 150.01 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.55 Bn | 101.38 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.31 Bn |
| Dec 31, 2025 | 8.57 Bn |
| Jun 30, 2025 | 8.01 Bn |
| Dec 31, 2024 | 8.07 Bn |
| Jun 30, 2024 | 8.00 Bn |
| Dec 31, 2023 | 7.88 Bn |
| Jun 30, 2023 | 8.02 Bn |
| Dec 31, 2022 | 6.95 Bn |
| Jun 30, 2022 | 7.00 Bn |
| Dec 31, 2021 | 7.07 Bn |
| Jun 30, 2021 | 6.47 Bn |
| Dec 31, 2020 | 6.31 Bn |
| Jun 30, 2020 | 5.42 Bn |
| Dec 31, 2019 | 133.27 Mn |
| Jun 30, 2019 | 5.71 Bn |
| Dec 31, 2018 | 5.75 Bn |
| Jun 30, 2018 | 69.22 Mn |
| Mar 31, 2018 | 5.32 Bn |
| Dec 31, 2017 | 5.46 Bn |
| Jun 30, 2017 | 4.73 Bn |